Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced three oral presentations by academic collaborators at the 29th International Congress of The Transplantation Society (TTS 2022) being held September 10-14, 2022 in Buenos Aires, Argentina, and virtually. Copies of the presentations will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
Oral Presentation Details
| Title: | Long-term rejection free renal allograft survival with Fc-modified anti-CD154 antibody monotherapy in nonhuman primates |
| Date: | Monday, September 12, 2022 |
| Time: | 4:35 p.m. EDT (17:35 ART) |
| Session: | Campfire Session: Models, mechanisms & therapies |
| Presenter | Grace Lassiter, M.D., Research Fellow of the Kawai Lab |
| Title: | Monotherapy with TNX-1500, a Fc-modified anti-CD154mAb, prolongs cardiac allograft survival in cynomolgus monkeys |
| Date: | Tuesday, September 13, 2022 |
| Time: | 3:25 p.m. EDT (16:25 ART) |
| Session: | Mini-Oral Abstracts Session: Snap-shots of thoracic transplantation |
| Presenter | Kohei Kinoshita, M.D., Research Fellow of the Pierson Lab |
| Title: | Long-term (>1 year) rejection/TMA free survival of kidney xenografts with triple xenoantigen knockout and multiple human transgenes in nonhuman primates |
| Date: | Wednesday, September 14, 2022 |
| Time: | 10:00 a.m EDT (11:00 ART) |
| Session: | Mini-Oral Abstracts Session: Xenotransplantation |
| Presenter | Grace Lassiter, M.D., Research Fellow of the Kawai Lab |
